<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: DX-8951f is a novel hexacyclic <z:chebi fb="0" ids="27656">camptothecin</z:chebi>-analogue <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi> with both in vitro antileukemic activity and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> as a dose-limiting toxicity in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> Phase I studies </plain></SENT>
<SENT sid="1" pm="."><plain>DX-8951f is active in a human <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) severe combined immunodeficient mouse model </plain></SENT>
<SENT sid="2" pm="."><plain>In a <z:hpo ids='HP_0001909'>leukemia</z:hpo> Phase I study, we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: DX-8951f was given as an i.v. infusion over 30 min daily for 5 or 7 days </plain></SENT>
<SENT sid="4" pm="."><plain>The starting dose was 0.6 mg/m(2)/day for 5 days (3.0 mg/m(2)/course) </plain></SENT>
<SENT sid="5" pm="."><plain>Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Twenty-five patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 21 patients; <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 1 patient; <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 2 patients; <z:mp ids='MP_0005481'>CML</z:mp>-BP, 1 patient) were treated </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0010280'>Stomatitis</z:hpo> was the dose-limiting toxicity, occurring in two of two patients treated at 1.35 mg/m(2)/day for 5 days, two of three treated at 1.2 mg/m(2)/day for 5 days, and one of six treated at 0.9 mg/m(2)/day for 7 days </plain></SENT>
<SENT sid="8" pm="."><plain>The recommended Phase II dose was 0.9 mg/m(2)/day for 5 days </plain></SENT>
<SENT sid="9" pm="."><plain>The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Phase II studies are warranted to further define the activity of DX-8951f in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>